Close

Eagle Pharmaceuticals (EGRX) Announces Strong Preclinical Data on Ryanodex as MDMA-Related Hyperthermia Treatment

Go back to Eagle Pharmaceuticals (EGRX) Announces Strong Preclinical Data on Ryanodex as MDMA-Related Hyperthermia Treatment

Eagle Pharmaceuticals Announces Positive Initial Results of Animal Study Exploring Use of Ryanodex in MDMA (Ecstasy) Induced Hyperthermia Conducted at the National Institutes of Health

October 31, 2016 7:00 AM EDT

-- Ryanodex-treated animals experienced a greater decrease in brain temperature from peak temperature values, compared to animals in the control group

- Brain temperature in Ryanodex-treated animals returned to baseline --

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) (Eagle or the Company) today announced initial results from the preclinical study conducted by Eagle at the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH) exploring the use of Ryanodex® in the treatment of hyperthermia related to MDMA (Ecstasy) intoxication. The study was conducted in the summer of 2016... More